Maxim Group analyst Jason McCarthy has maintained their bullish stance on MTVA stock, giving a Buy rating yesterday.
Jason McCarthy’s rating is based on several promising developments within MetaVia’s pipeline, particularly in their obesity and MASH programs. The company has made significant strides with DA-1726, an oxyntomodulin analog targeting obesity, which has shown potential for superior weight loss and better tolerability compared to existing treatments. The ongoing Phase 1 study is expected to provide further positive data in April 2025, which could act as a catalyst for the stock.
Furthermore, MetaVia’s DA-1241 program targeting MASH has also demonstrated encouraging results, with plans to engage with the FDA for further steps. Despite broader market challenges affecting small and micro-cap biotech valuations, McCarthy maintains a positive outlook on MetaVia’s fundamentals. He acknowledges the need for future capital raising but remains optimistic about the company’s strategic direction and potential growth, thus supporting his Buy rating.
According to TipRanks, McCarthy is an analyst with an average return of -17.5% and a 26.87% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Medicus Pharma Ltd, Lipella Pharmaceuticals, Inc., and SELLAS Life Sciences Group.
In another report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $12.00 price target.